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OBJECTIVE—We have developed a new antihyperglycemic
agent (teglicar) through the selective and reversible inhibition
of the liver isoform of carnitine palmitoyl-transferase 1 (L-CPT1).
RESEARCH DESIGN AND METHODS—Glucose production
was investigated in isolated hepatocytes and during pancreatic
clamps in healthy rats. Chronic treatments on C57BL/6J, db/db,
high-fat fed mice, and rats were performed to understand glucose
metabolism and insulin sensitivity.
RESULTS—In isolated hepatocytes, teglicar concentration de-
pendently reduced ketone bodies and glucose production up to
72 and 50%, respectively. In rats, teglicar reduced the endogenous
glucose production (262%) without affecting peripheral glucose
utilization. Heart 2-[
3H]deoxyglucose uptake in mice was also not
affected, conﬁrming in vivo the drug selectivity toward L-CPT1.
Chronic treatment in db/db mice (50 mg/kg/bid; 45 days) reduced
postabsorptive glycemia (238%), water consumption (231%),
and fructosamine (230%). Such antidiabetic activity was associ-
ated with an improved insulin sensitivity assessed by the insulin
tolerance test. A signiﬁcant 50% increase in hepatic triglyceride
content (HTGC) was found, although plasma alanineaminotrans-
ferase was not altered. In addition, long-term teglicar administra-
tion to high-fat fed C57BL/6J mice normalized glycemia (219%)
and insulinemia (253%). Long-term teglicar administration (30
days, 80 mg/kg) in healthy overnight-fasted rats slightly reduced
basal glycemia (220%, ns), reduced basal insulin levels by 60%,
doubled triglycerides, and increased free-fatty acids (153%).
HTGC was markedly increased, but liver and peripheral insulin
sensitivity assessed by hyperinsulinemiceuglycemic clamp were
not affected.
CONCLUSIONS—Teglicar, in vitro and in animal models,
reduces gluconeogenesis and improves glucose homeostasis,
refreshing the interest in selective and reversible L-CPT1 in-
hibition as a potential antihyperglycemic approach. Diabetes
60:644–651, 2011
F
asting hyperglycemia presented by severe type 2
diabetic patients (glucose .9 mmol/L) is largely
a function of increased endogenous glucose
production (EGP) (1–3).
Pharmacological reduction of hepatic gluconeogenesis
(GNG), which markedly contributes to high EGP, is con-
sidered one of the main targets in treating diabetes (4); in
fact, the therapeutic effect of the most widely prescribed
drug, metformin, is mainly due to its inhibitory effect on
GNG (5).
Various studies have shown that inhibition of fatty acid
oxidation in humans by blocking carnitine palmitoyl-
transferase 1 (CPT1) (6–8) or by decreasing lipolysis (9,10)
may reduce EGP and fasting glycemia. The oxidation of
fatty acids provides energy (ATP) and reducing equiv-
alents (NADH), and it stimulates GNG through structural
changes in pyruvate carboxylase via increased levels of
acetyl-CoA (11).
CPT1 (12) is a ubiquitous enzyme that plays a pivotal
role in mitochondrial fatty acid b-oxidation. It is part of the
carnitine palmitoyl-transferase system, which enables the
activated acyl-CoA to be transported inside the matrix,
crossing the inner mitochondrial membrane. It catalyzes
the trans-esteriﬁcation of acyl-CoA into acyl-carnitine,
which permeates the mitochondrial membrane by a spe-
ciﬁc carrier mechanism and reacts with a matrix pool of
CoA in a reaction catalyzed by CPT2 on the inner face of
the inner membrane. The reformed acyl-CoA then enters
the b-oxidation pathway, while the released carnitine
returns to the extramitochondrial compartment. At a more
complex level, growing evidence (13–15) supports the
hypothesis of CPT1 activity as being part of the hypotha-
lamic machinery involved in sensing nutrient availability,
which in turns affects feeding behavior and endogenous
glucose production.
Etomoxir, a CPT1 inhibitor with hypoglycemic activity
in diabetic patients, was abandoned because of its inability
to distinguish between the liver (L-CPT1) and the muscle
(M-CPT1) isoform of CPT1, causing undesirable cardiac
effects (16) and, possibly, muscle insulin resistance (17).
Therefore, selectivity between the two isoforms of CPT1 is
a major issue.
We have previously reported the discovery of the
new substrate mimetic aminocarnitine derivative teglicar
(ST1326) (18), as a more selective and reversible L-CPT1
inhibitor (half-maximal inhibitory concentration [IC50]=
0.68 6 0.13 mmol/L, Ki =0 . 3 66 0.04, enhanced CPT1
selectivity ratio [;70]), with respect to other previously
described compounds (19–21).
The presently reported studies are aimed at the assess-
ment of the effects of teglicar on glucose production, in-
sulin sensitivity, and heart glucose metabolism, both in
vitro and in animal models of diabetes in vivo, to address
not only its hypoglycemic properties but also the potential
consequences of sustained liver CPT1 inhibition.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Animals and diets. SD 12-week-old male rats were purchased from Charles
River (Calco, Italy). BKS db/db and C57BL/6J 8-week-old male mice were
purchased from Jackson Laboratory (Bar Harbor, ME). SD rats and BKS db/db
mice were fed ad libitum with a standard diet (No. 4RF21 Mucedola; Settimo
Milanese, Italy), whereas high-fat-fed C57BL/6J mice received a fatty diet (58%
fat kcal, No. 12331-Research Diets; New Brunswick, NJ) ad libitum for 7 months.
All animal experiments were conducted in accordance with European Di-
rective nr 86/609 and Italian D.L. nr 116, 27 January 1992. All procedures
were reviewed and approved by our internal animal studies committee and
comply with the Principles of Laboratory Animal Care (National Institutes of
Health publication No. 85-23, Revised 1985).
Blood and tissue collection, serum and tissue analysis. Blood samples in
mice were taken by a tail-tip withdrawal. Tissues were quickly isolated, frozen
in liquid nitrogen, and stored at 280°C for subsequent analysis. Glucose was
measured by the hexokinase method (HK125, ABX Diagnostics), and ketone
bodies, fructosamine, triglycerides, free fatty acids (FFA), cholesterol, and se-
rum liver enzyme activities were measured by commercial colorimetrics kits.
Insulin was measured by radioimmunoassay using rat insulin standards, which
shows 100% cross-reaction with mouse insulin (Biotrack RPA-547, Amersham).
Tissue triglycerides were extracted with isopropanol (22) and measured as
above. Glycogen content was determined by the Mauvais-Jarvis method (23).
Hepatocyte isolation and incubation. Hepatocytes were isolated by colla-
genase digestion (24) from rats fasted for 16 h. Because rat liver glycogen
stores are almost absent (24) after a 16-h fast, the quantity of cumulative
glucose and ketones bodies released into Krebs medium by fresh isolated
hepatocytes is a good indicator of GNG and ketogenesis, respectively. Cells
(1*10
6/mL) were incubated (25) in closed vials in an O2/CO2 (19:1) atmosphere
at 37°C in a shaking water bath in a Krebs bicarbonate buffer containing:
10 mmol/L lactate and 1 mmol/L pyruvate, which guarantee GNG; 1 mmol/L
glucose; 2% BSA and 2 mmol/L l-carnitine. After 30 min of preincubation with
teglicar at different concentrations, 1 mmol/L sodium oleate was added to ac-
tivate b-oxidation and pyruvate carboxylase. The effect of selected concen-
trations of teglicar on hepatocytes exposed to different concentrations of lactate
and pyruvate, always in a 10:1 ratio, was also tested. Incubation was stopped 2 h
later by precipitation in 3% perchloric acid. Once neutralized by KOH and
centrifuged, medium-accumulated glucose and ketone bodies were measured.
Clamp procedure in rats. One week before study, male SD rats underwent
surgery to implant indwelling catheters in the internal jugular vein and carotid
artery. Recovery was monitored by measuring daily food consumption and
weight gain for 4 to 5 days after surgery.
Pancreatic clamp. Pancreatic clamps were performed at 10:00 A.M. in con-
scious, 7-h-fasted, unrestrained SD rats. At time 0, a prime continuous infusion
of [3-
3H]glucose (NEN Dupont, Boston, MA [40 mCi bolus, 0.4 mCi/min for the
duration of the study]), insulin (0.7 mU/kg/min), somatostatin (15 mgb o l u s ,
1.5 mg/kg/min), and saline (0.5 mL/h) was started. The rate of insulin infusion
was designed to replace normal basal levels in postabsorptive rats. Once
steady state was achieved (EGP1) (after 2 h), in the treated group the saline
was switched to teglicar (5.3 mg/kg/h) for further 3 h (EGP2). Euglycemia
(7.5 mmol/L) was maintained by a variable infusion of 25% glucose solution.
Sampling frequency, for determination of [3-
3H]glucose–speciﬁc activity, was
increased at 5-min intervals 20 min before end points EGP1 and EGP2.
Hyperinsulinemic-euglycemic clamp. To assess the effect of chronic treat-
ment with the drug on hepatic and peripheral insulin sensitivity, SD rats
wereorallytreatedonceadaywithteglicar(80mg/kg)for30days.Clampswere
performed at 10:00 A.M. After an overnight fast, conscious unrestrained rats
received a primed continuous infusion of [3-
3H]glucose (40 mCi bolus, 0.4 mCi/
min) to set basal condition. At 2 h, a primed continuous infusion of insulin
(15 mU bolus, 3 mU/kg/min) and somatostatin (15 mgb o l u s ,1 . 5mg/kg/min) was
started and continued for 3 h. The euglycemia was maintained with a variable
infusion of 25% glucose solution. The determination of [3-
3H]glucose–speciﬁc
activity was performed as described above. Following these procedures, rats
were anesthetized (55 mg/kg body wt iv, pentobarbital) and killed, and liver
tissue samples were excised and cooled in liquid nitrogen. Samples were
stored at 280°C for subsequent analysis.
Heart 2-[
3H]deoxyglucose uptake. Postabsorptive C57BL6/J mice were
acutely treated by gavage with 50 mg/kg teglicar or etomoxir. The long-term
treatment was performed by administering teglicar at 100 mg/kg/day for
30 days. Three hours postdose, 2-[
3H]deoxyglucose (2-DG) was injected into
the tail vein. Heart glucose uptake was measured by the Kraegen method (26).
Long-term treatment of db/db mice and insulin tolerance test. Teglicar at
the dose of 50 mg/kg twice a day was administered by gavage to 8-week-old
db/db mice. Daily food intake and water consumption were measured and
reported as average over 45 days. Postabsorptive glycemia was measured after
28, 35, and 45 days of treatment. Animals were then killed, after 8-h fast, and
liver tissue was collected, frozen, and stored at 280°C.
The insulin tolerance test (ITT) was perfomed on the 40th day of treatment
on fed mice by injection of 1 U/kg body wt ip insulin (Humulin R, Eli-Lilly,
Indianapolis, IN). Glucose in tail vein blood was measured immediately before
injection (time 0) and at 20, 40, and 60 min after injection (One Touch Ultra
glucometer; Lifescan, Milpitas, CA). The blood glucose area under the curve
(AUC) was calculated using the trapezoidal rule.
Long-term treatment of high-fat diet C57BL/6J mice. C57BL/6/J male
mice,previouslyfedfor7monthswithhigh-fatdiet(startingfromtheir8thweek
of life), were treated for 26 days with 30 mg/kg teglicar, or vehicle, twice a day.
Glucose, insulin, triglycerides, FFAs, and cholesterol serum levels were then
estimated in postabsorption state (fasting from 11:00 A.M. to 4:30 P.M.), 8 h from
the last treatment. After 15 days of treatment, animals were subjected to an
oral glucose tolerance test (OGTT), receiving a single bolus of 30% glucose
solution (3 g/kg) by gavage. Blood was withdrawn 5 h from last treatment and
after 5 h fasting, at 0, 30, 60, 90, and 120 min.
Evaluation of proliferator-activated receptor a activation after long-
term treatment. To exclude the hypothesis of a counterregulatory effect of
prolonged teglicar treatment on proliferator–activated receptor a (PPAR-a),
PPAR-a and its target gene product medium chain acyl-CoA dehydrogenase
(MCAD), were quantiﬁed by Western blot densitometric analysis using rabbit
anti-MCAD polyclonal antibody (Alexis Corporation, San Diego, CA) and
mouse monoclonal anti-PPAR-a antibody (Afﬁnity BioReagents, Golden, CO),
respectively, in tissues of db/db mice after 45 days of treatment (50 mg/kg
twice per day). Fresh crude peroxisomal fractions (livers were homogenated
in buffered 0.32 mol/L sucrose; once pelleted the cellular debris, crude per-
oxisomes were pelleted at 15,000 3 g per 15 min and resuspended in sucrose
buffer) were assayed using [
14C]U-Palmitoyl-CoA as substrate. Potassium cy-
anide was added in the assay buffer to detect only b-oxidation from perox-
isomes as described by Lazarow (27).
Statistical analysis. All values are presented as the mean 6 SE. The Stu-
dent t test was used to determine the difference between control and
treatment groups. Signiﬁcance was accepted as P , 0.05. For multiple
comparisons between groups, a one-way ANOVA followed by Dunnett test
was performed.
RESULTS
Effects of teglicar on ketone bodies and b-oxidation-
dependent glucose production in isolated hepatocytes.
Teglicar induced a concentration-dependent reduction of
ketone bodies and glucose production by hepatocytes
incubated with 10 mmol/L lactate and 1 mmol/L pyruvate
(Fig. 1A). At 10 mmol/L teglicar, ketone bodies production
was reduced by 72% (effective dose 50 = 1.17 6 0.12 mmol/
L), whereas cumulative glucose in the medium diminished
up to 50% with respect to the untreated cells. The residual
glucose production, independent from b-oxydation (we ob-
tained similar results with etomoxir and 2-tetradecylglycidic
acid (TDGA), data not shown), may be affected by changing
lactate and pyruvate concentrations (Fig. 1B).
Effects of teglicar on endogenous glucose production
in SD rats. The pancreatic clamp was set up as shown in
Fig. 2A to assess the effect of the drug on EGP. After basal
EGP (EGP1) during the ﬁrst 120 min of clamp (9.1 6 1.2
and 10.5 6 1.15 mg/kg/min, in saline and treatment group,
respectively) was measured, a 3-h teglicar infusion was
administered. In the ﬁrst 60 min the drug infusion de-
termined a rapid drop in glycemia (Fig. 2B), requiring
a coinfusion of 25% glucose to restore and maintain pre-
viously measured glucose values. At the end of the clamp
session, teglicar-suppressed EGP (EGP2) diminished by
62% (Fig. 2C), whereas peripheral glucose utilization (GU)
was not affected (8.4 6 1.2 saline vs. 9.69 6 1.31 mg/kg/
min teglicar).
Effects of teglicar on insulin sensitivity in SD rats. To
better deﬁne the impact of long-term L-CPT1 inhibition on
insulin resistance, healthy SD rats were treated with 80
mg/kg/day teglicar for 30 days; treatment did not produce
differences in food intake or ﬁnal weight. Teglicar reduced
basal insulin levels; a nonsigniﬁcant trend toward a reduction
of basal blood glucose was also observed, whereas EGP,
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tivity (GU), assessed with a hyperinsulinemic-euglycemic
clamp, did not differ between treated animals and con-
trols. In contrast, plasma FFA and triglycerides increased
but quickly return to normal values in hyperinsulinemic
conditions. After death, treated rats showed a higher tri-
glyceride and lower glycogen content in the liver, without
any change in liver weight (Table 1).
Effects of teglicar on heart glucose uptake in vivo in
C57BL/6J mice. To rule out the possibility of any effect of
teglicar heart glucose metabolism, heart 2-DG uptake was
measured after both single dose (50 mg/kg) and long-term
treatment (30 days at 100 mg/kg/day) in C57BL/6J mice;
oral etomoxir (50 mg/kg) was used as positive control in
the single-dose experiment. Figure 3A clearly shows that
etomoxir causes a massive switch in cardiomyocyte me-
tabolism. Although etomoxir-induced M-CPT1 inhibition
caused a 12-fold increase in heart 2-DG uptake, teglicar did
not modify this parameter (Fig. 3A). Long-term, effective
treatment with teglicar failed to determine signiﬁcant
changes in 2-DG heart uptake, heart weights, and tri-
glyceride content (Fig. 3B).
Long-term effects of teglicar on murine models of
diabetes—db/db mice. Teglicar treatment (50 mg/kg twice
per day for 45 days) induced a signiﬁcant reduction (up to
50%) of postabsorptive serum glucose, which was evident
after 28 days of treatment and lasted throughout the ex-
periment. Consistent with the improvement of glucose
control, serum fructosamine and average daily water con-
sumption were also reduced, underlining an improvement
in long-term glycemic control. Serum FFAs were slightly
increased, 10% more than controls, whereas insulin levels,
triglycerides, alanine aminotransferase, and cholesterol did
not change. Food intake showed a nonsigniﬁcant trend to-
ward reduction, but body weight was not affected in treated
mice. After death, hepatic triglyceride content, but not liver
weight, was moderately increased (Table 2). Teglicar also
induced a signiﬁcant reduction of glucose AUC during ITT
in comparison with controls (Fig. 4).
Long-term effects of teglicar on murine models—
high-fat diet C57BL/6J mice. The effects of teglicar
were also studied in a further model of insulin resistance
and hyperglycemia, induced by feeding C57BL/6J mice
with a high-fat diet; a low-fat diet (8% Kcal from fat) un-
treated control group was also included.
Treating mice fed high-fat diet with teglicar (30 mg/kg
twice per day for 26 days) did not affect food intake and
body weight (not shown). Serum FFAs and triglycerides,
unlike the previous data on db/db mice, did not change.
The diabetogenic effects of high-fat diet on glucose and
insulin serum levels were abolished by teglicar (219%
glycemia and 253% insulinemia; Table 3). As expected,
mice fed high-fat diet were overtly glucose intolerant
during the OGTT test with respect to mice fed low-fat diet.
Teglicar did not affect this parameter although a slight
trend toward reduction was seen (Fig. 5).
Long-term effects of teglicar on PPAR-a activation
and hepatic peroxisomal b-oxydation. Teglicar treat-
ment for 45 days did not induce any variation in the con-
tent of PPAR-a and its target gene product MCAD in liver
and heart of db/db mice (Fig. 6A). Measurements of per-
oxisomal b-oxidation in the liver also did not show any
signiﬁcant differences between groups (Fig. 6B).
DISCUSSION
Teglicar, a selective and reversible inhibitor of liver CPT1,
reduced both ketogenesis and glucose production in
freshly isolated hepatocytes prepared from fasted rats.
This cellular effect on glucose production was further
corroborated by in vivo experiments with pancreatic
clamp, showing that teglicar acutely reduces hepatic glu-
cose production without interfering with peripheral GU, as
expected by its selectivity for liver isoform. In fact, an in-
crease of peripheral GU would be indicative of an ongoing
reversed Randle effect (28,29) through inhibition of M-
CPT1. A more accurate analysis of cardiac muscle metab-
olism in mice revealed that, even after full-dose long-term
FIG. 1. A: Teglicar-dependent suppression of glucose and ketone bodies production by hepatocytes isolated from 16-h-fasted rats and incubated in
presence of 10:1 lactate/pyruvate and 1 mmol/L oleate. B: Relationship between hepatocytes glucose production and the concentration of pyruvate/
lactate in Krebs medium containing 1 mmol/L oleate in the presence or absence of 10 mmol/L teglicar. Each point represents the mean 6 SE from
eight different hepatocyte preparations in triplicate: ***P < 0.001; **P < 0.01 vs. control (CTRL) + oleate.
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uptake were not affected, further excluding the concern
of heart hypertrophy and muscle insulin resistance due to
M-CPT1 inhibition as reported for etomoxir (16,17,30).
The chronic administration of the drug conﬁrmed its
antihyperglycemic action in db/db mice, a well-established
murine model of type 2 diabetes, with a reduction of fast-
ing plasma glucose, serum fructosamine, and daily water
intake. Body weight did not change but a slight not sig-
niﬁcant reduction of food intake was observed, mostly
explained by a decreased calories waste through glycosuria.
The improvement of insulin sensitivity observed in treated
animals with the ITT could be interpreted as an indirect
consequence of ameliorated metabolic control, with re-
duced glucose toxicity. The effects of teglicar were investi-
gated also in a different animal model, the hyperglycemic
high-fat-fed C57BL/6J mice, which are characterized by obe-
sity, hyperinsulinemia, hyperleptinemia, and hyperglycemia
and resemble more closely human type 2 diabetes. Being
insulin resistance and hyperglycemia determined by pro-
longed high-fat feeding, this model can be considered as
particularly challenging for a compound interfering with
fatty acid oxidation. The antidiabetic activity of the com-
pound was conﬁrmed in this model, which yielded similar
results as those obtained in db/db mice, in terms of gly-
cemia and insulin reduction, but without further compro-
mising the serum lipid asset.
The inhibition of L-CPT1 induced, as expected, a sig-
niﬁcant increase in fat liver content (marked in fasted
healthy rats, moderate in db/db mice). The marked in-
crease observed in healthy rats may anyway be conﬁned
to the prolonged fasting condition, where teglicar, by
reducing ketogenesis and gluconeogenesis, puts at risk
glucose homeostasis. However, fasting normoglycemia was
maintained by the important reduction of plasma insulin,
w h i c hc o n s e q u e n t l yw a sr e s p o n s i b l ef o rt h ei n c r e a s eo f
FIG. 2. A: Pancreatic clamp procedure involves the infusion of 0.4 mCi/min [3-
3H]glucose, 1.5 mg/kg/min somatostatin, and 0.7 mU/kg/min insulin.
Control rats received saline throughout the experiment, whereas teglicar infusion was started at 120’. Rats receiving the drug also received
glucose to prevent hypoglycemia. B: Representation of teglicar-induced drop in glycemia during pancreatic clamp. Euglycemia is restored by
glucose coinfusion. C: Rates of glucose production before (EGP1) and during (EGP2) the infusion of teglicar (white bars) or saline (black bars) in
postabsorptive SD rats. The box plots indicate the mean 6 SE from ﬁve different pancreatic clamps/group. *P < 0.05 vs. saline.
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liver steatosis.
Despite this fact, teglicar does not induce insulin re-
sistance.
Even if increased hepatic triglyceride content is com-
monly thought to be associated with reduced insulin sen-
sitivity (31), our evidence are in agreement with the results
of studies in which liver steatosis induced by acute
treatment with TDGA in C57BL/6J mice, or with methyl-
palmoxirate in hyperlipidemic APO3*Leiden mice, does
not induce liver insulin resistance (32,33). In addition,
Buettner et al. (34) perfusing ex vivo livers from high-fat-
fed Wistar rats showed that increased intracellular lipids
per se do not induce defects in insulin action, reporting
that fasting-induced hepatic steatosis is not associated
with an impairment of liver insulin sensitivity in healthy
rodents (35), suggesting alternative extrahepatic regu-
lators of liver insulin sensitivity other than triglycerides.
This last concept was also recently proposed by Wendel
et al. (36), which clearly showed that preventing hepatic
steatosis in ob/ob mice, by deleting glycerol-3-phosphate
acyltransferase-1 (Gpat1), does not improve insulin sen-
sitivity. Hormones from adipose tissue and a primary
central nervous system control may be responsible for this
alternative regulation.
In this regard, it has been reported (Obici et al. [37]) that
by reducing the activity of the hypothalamic L-CPT1
through injection of a ribozyme-containing plasmid into
the third ventricle of the rat, designed to reduce the ex-
pression of the enzyme, or by infusing teglicar (5 or 25
pmol), a decrease in food intake and glucose production
was induced. More recently, the structure of feeding be-
havior and satiation time course were examined in mice
after teglicar intracerebroventricular treatment, evidenc-
ing that the signiﬁcant anorectic response is mirrored by
an early occurrence of satiety onset (38). Anyway, because
of its chemico-physical characteristics, teglicar is not likely
to cross the blood-brain barrier, and the results of the pres-
ently reported experiments failed to support the evidence
of such central control of glucose production and appetite.
However, in our opinion at least a slight hypothalamic
L-CPT1 inhibition during chronic therapy in humans cannot
be completely excluded without further investigation, since
in the long term the hypothalamic concentration of the drug
could achieve the extremely low levels required.
The results of our research sustain the hypothesis that
selectively targeting L-CPT1 could represent an effective
TABLE 1
Effect of 30 days of teglicar treatment before and during insulin
infusion (3 mU/min/kg) on plasma glucose, lipid, and liver
parameters in overnight-fasted, conscious, unrestrained SD rats
Control Teglicar
Glucose (mg/dL)
Basal 114.3 6 9.2 92.0 6 4.9
Clamp 91.5 6 5.2 87.0 6 3.8
Insulin (ng/mL)
Basal 1.12 6 0.44 0.45 6 0.04*
Clamp 4.14 6 0.35 4.02 6 0.36
FFA (mmol/L)
Basal 1214 6 112 1868 6 212*
Clamp 214 6 70 184 6 17
Triglycerides (mg/dL)
Basal 33.9 6 1.4 70.9 6 18*
Clamp 13.8 6 3.7 12 6 1.2
EGP (mg/kg/min)
Basal 7.41 6 0.45 7.82 6 0.46
Clamp 0.21 6 0.11 0.15 6 0.09
GU (mg/kg/min) 26.7 6 1.12 28.4 6 1.51
GIR (mg/kg/min) 26.9 6 1.05 28.3 6 1.63
Liver parameters at the end of clamp session
Liver weight (g) 17.2 6 1.2 18.1 6 1.4
Liver triglyceride
content (mg/100 mg wt) 0.42 6 0.1 5.3 6 0.7*
Liver glycogen (mmol/g wt) 50.5 6 4.1 20.1 6 1.4*
Data are means 6 SE of 6 rats/group. *P , 0.05 vs. controls.
FIG. 3. A: Heart 2-DG uptake in C57BL/6J mice after a single administration of teglicar (50 mg/kg) or etomoxir (50 mg/kg). The box plots are
expressed as micromoles of 2-DG incorporated per 100 grams wet tissue per minute 6 SE obtained from eight animals/group. ***P < 0.001 vs.
controls. B: Effect of long-term (30 days) teglicar administration (100 mg/kg/day) on heart 2-DG uptake, heart weight, and heart triglyceride (TG)
content in C57BL/6J mice. The box plots are expressed in percentage with respect to controls 6 SE obtained from six animals/group.
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abetes. This is supported also by the fact that a rare dis-
order of L-CPT1 deﬁciency in the Canadian Hutterite
population is not easily recognized, due to lack of disease-
speciﬁc metabolic markers other than hypoketotic hypo-
glycemia during fasting (39,40). Another L-CPT1 mutation
was identiﬁed in humans (41), which causes total inac-
tivation of L-CPT1, leading to life-threatening nocturnal
hypoglycemia without other signs of illness. These data, if
from one side conﬁrm the potential of L-CPT inhibition as
a mean for reducing gluconeogenesis in humans, on the
other end could raise concern about the possibility of
fasting-induced hypoglycemia. In our experiments in di-
abetic mice or normal rats fasting, hypoglycemia was not
recorded. This may be ascribed to the reversible nature of
teglicar inhibition, compared with the constitutional lack
of enzymatic activity. We also have evidence that even if
in 36-h fasting healthy volunteers no hypoglycemia was
observed (data not shown).
In conclusion the reported data demonstrate that tegli-
car, in vitro and in animal models, reduces gluconeogen-
esis and is able to improve glucose homeostasis, refreshing
the interest in selective and reversible L-CPT1 inhibition
as a potential antihyperglycemic approach. The recent
discovery (42) that metformin reduces hepatic gluconeo-
genesis independently of the LKB1/AMPK pathway, which,
instead, blunts metformin efﬁcacy, opens up the possibility
of an advantageous association with L-CPT1 inhibitors.
TABLE 2
Effect of teglicar treatment on different parameters of db/db mice
after long-term treatment (45 days unless otherwise speciﬁed)
Control Teglicar
Body weight (g) 40.0 6 1.1 40.4 6 2.2
Food intake (g/day) 6.71 6 0.2 5.46 6 0.4
Water intake (mL/day) 13.5 6 0.2 9.38 6 1.1*
Serum parameters
Glycemia (day 28) (mg/dL) 495 6 28 250 6 20*
Glycemia (day 35) (mg/dL) 570 6 30 322 6 25*
Glycemia (mg/dL) 576 6 32 352 6 25*
Fructosamine (mmol/L) 4.8 6 0.1 3.36 6 0.3*
Insulin (ng/mL) 2.81 6 0.2 2.32 6 0.3
Triglycerides (mg/dL) 80.7 6 5.5 82.2 6 6.1
FFA (mmol/L) 1.98 6 0.15 2.29 6 0.1*
Cholesterol (mg/dL) 110.4 6 10.1 112.4 6 6.1
ALT (U/L) 82.9 6 4.9 102.6 6 7.2
Liver parameters
Liver weight (g) 1.94 6 0.08 1.93 6 0.09
Liver triglyceride content
(mg/100 mg wt) 5.71 6 0.9 8.54 6 0.7*
Liver glycogen (mmol/g wt) 329 6 54 255 6 46
Data are means 6 SE of eight mice. *P , 0.05 vs. controls.
FIG. 4. ITT in db/db mice after teglicar treatment. The small bar plot
indicates the AUC (0–60 min) of glycemia during the ITT. Teglicar,
black bar and circles; control, white bar and triangles. Data are
expressed as percentage variation from initial glucose and in the bar
plot as milligrams per deciliters per minute. Each point indicates the
mean 6 SE of eight mice. *P < 0.05 vs. controls.
TABLE 3
Effect of teglicar on postabsorptive serum parameters of C57BL/6J
mice fed with a high-fat diet
High-fat diet Low-fat diet
Control Teglicar Control
Glucose (mg/dL) 216.7 6 12.9 174.8 6 12.5* 178.7 6 11.8*
Insulin (ng/mL) 3.01 6 0.10 1.39 6 0.34** 1.46 6 0.29**
FFA (mmol/L) 725 6 58 780 6 31 690 6 46
Triglycerides
(mg/dL) 69.5 6 6.9 56.9 6 3.9 43.5 6 2.2**
Cholesterol
(mg/dL) 220.0 6 5.1 241.7 6 8.9 156.4 6 6.8**
Data are means 6 SE of ﬁve (teglicar treated) and six (high-fat and
low-fat control groups) mice group. *P , 0.05; **P , 0.01 vs. high-fat
diet group.
FIG. 5. Blood glucose levels during OGTT test on 5-h fasted male
C57BL/6J mice fed with a high-fat diet and treated with teglicar
(ST1326, 30 mg/kg, twice per day) for 15 days, at 5 h from last treat-
ment. Means are 6 SE (n = 6 for high-fat diet and low-fat diet; n = 5 for
high-fat diet + teglicar). ***P < 0.001; **P < 0.01 vs. high-fat diet group.
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teglicar, alone and in combination with other agents, in the
therapy of type 2 diabetes.
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